相关实验视频

Updated: Sep 9, 2025

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Imaging of In Situ Interferon Gamma Production in the Mouse Spleen following Listeria monocytogenes Infection

Published on: July 16, 2019

在小鼠败血症中,IGFBP6通过禁止因-2介导的免疫抑制来调节抗感染性免疫衰退

Kai Chen¹, Ying Hu¹, Xiaoyan Yu¹

¹Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University, Chongqing, China.

The Journal of clinical investigation

|September 2, 2025

概括

通过破坏免疫细胞功能,导致败血症的严重程度. 针对IGFBP6提供了新的败血症诊断和治疗策略,改善了患者的生存率.

科学领域:

免疫学
分子生物学
生物化学

背景情况:

败血症仍然是全球主要的死亡原因.
鉴定新生物标志物和败血症的治疗点至关重要.

研究的目的:

研究胰岛素类生长因子结合蛋白6 (IGFBP6) 在败血症发病过程中的作用.
评估IGFBP6作为毒症的诊断生物标志物和治疗点.

主要方法:

多中心跨年龄队列研究.
在体外和体内实验包括细胞培养和败血症小鼠模型.
包括PHB2,STAT1和Akt酸化在内的信号通路的分析.
对巨细胞功能,细菌清除率和生存率的评估.

主要成果:

IGFBP6被确定为败血症诊断,预后和死亡风险的关键调节者.
通过破坏PHB2-STAT1-CCL2轴,IGFBP6会影响巨细胞的化学反应.
通过破坏Akt酸化,降低ROS/ IL- 1β的产生和细胞能力,IGFBP6抑制了巨的杀菌活性.
沉默PHB2或激活STAT1恢复了CCL2表达,而Akt激动剂SC79则逆转了巨细胞功能障碍.
针对IGFBP6介导信号的干预措施改善了败血症小鼠的细菌清除和生存.

结论:

IGFBP6是败血症发病的一个内源驱动因素.
IGFBP6作为毒症的双重诊断生物标志物和治疗点.
针对IGFBP6介导的信号通路是治疗败血症的一个有希望的策略.

关键词:

免疫疗法感染性疾病炎症发生巨细胞

更多相关视频

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...